XERAVA

This brand name is authorized in Austria, Estonia, Ireland, Lithuania, Poland, Romania, United States

Active ingredients

The drug XERAVA contains one active pharmaceutical ingredient (API):

1 Eravacycline UNII WK1NMH89VJ - ERAVACYCLINE DIHYDROCHLORIDE

Eravacycline is an antibacterial drug. Its mechanism of action involves the disruption of bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains. Read about Eravacycline

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
XERAVA Powder for solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR
XERAVA Powder for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J01AA13		J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01A Tetracyclines → J01AA Tetracyclines
Discover more medicines within J01AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1781197, 1813665, 1842106, 1842117
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1086424, 1088260, 1092142, 1092143, 1092975
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100411958, 100461434
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69479001
Country: US	FDA, National Drug Code	Identifier(s): 71773-050, 71773-100